Articles On Genetic Signatures (ASX:GSS)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

If you have a high tolerance for risk, then the speculative ASX stock in this article could be worth considering. That's because it is being tipped to rise by over 50% from current levels over the next 12 months by analysts at Bell Potter....

ASX closes at new high of 9094 points, up 0.7pc Broad momentum across sectors with 10 of 11 higher US-Australian critical mineral deals fuel more resource stock gains   ASX roars to new highs on US-Australia rare earths deal The ASX 200 s...

Genetic Signatures (ASX: GSS) has reported a strong start to the new financial year with the commercial success of its EasyScreen gastrointestinal parasite detection testing kit across all operating regions, and a 20% increase in sales for...

While sector conditions are improving, investors still can pick up marked-down, revenue-generating biotechs Dozens of offshore life science plays trade at below net asset backing, but the discounts on the ASX aren’t quite so harsh Investor...

Nexsen is commercialising novel point-of-care diagnostic tech developed by RMIT University The company’s first target is group B streptococcus (GBS) bacteria, a potentially dangerous disease affecting one in six pregnant women. Nexsen is...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

The life sciences stocks that boomed during the pandemic have applied their experience to fresh approaches  Self-test Covid assay developers are finding success with other indications   While far from the ‘good ol’ days’, the pandemic taug...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Genetic’s company-making US expansion proves harder than expected BTC Health makes a (literally) lifesaving sale The lessons from Sarepta’s billion-dollar FDA woes   Gut disease diagnostics provider Genetic Signatures (ASX:GSS) is finding...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff...

Highlights: Australian shares experience market fluctuations, leading to discussions about undervalued stocks. Companies with significant discounts based on estimated fair values are being examined. Various sectors, includin...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlights: Diverse Sector Performances: Companies across mining, retail, technology, and financial services provided detailed updates on operations and strategic directions.COG Financial Services Retail and Travel Developments: Major...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((29M)) - 29Met...

Highlights: The stock price of Genetic Signatures Limited has experienced an upward movement this week. Over the past several years, revenue has shown a downward trend, impacting overall stock performance. Recent share acquisitions by...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck By Rudi Filapek-Vandyck, Editor Analysts at Ord Minnett have updated...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Pro Medicus’ growth story is far from over. How should investors deal with the valua...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Painchek is eyeing a market of 1.7 million US aged-care beds for its pain-detection device Genetic Signatures sizes up a $400 million US market The latest thrills and spills at life sciences AGMs   PainChek (ASX:PCK) lodged a US Food &amp...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from James McDona...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today’s Reports: ((AIS)) – Aeris...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Now could be the time to pounce on one small cap ASX stock if your risk tolerance allows for it. That's the view of analysts at Bell Potter, which believe this speculative stock could have a "lucrative opportunity" in the United States. Whi...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

Molecular diagnostics company Genetic Signatures (ASX:GSS) has announced that the US FDA has cleared its EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated workflow for marketing and sale in the US.

Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang   Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact...

It was a tough start to the week for the St Barbara Ltd (ASX: SBM) share price. The ASX gold stock was down as much as 21% to 22 cents before eventually closing the session at 23.5 cents. Why did this ASX gold stock crash? Investors were hi...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

By now, all Australians would be aware of the woes that high inflation has brought upon us. After virtually disappearing as an economic concern for a decade, the post-pandemic era saw inflation rear its ugly head once more. This could have...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.75% to 7,784.4 points. Four ASX shares that have failed to follow the market higher today a...

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

Stock market crashes can cause a lot of pain when they do occasionally occur. When a crash happens, there's widespread and indiscriminate selling by fearful investors. While living through a bear market is unsettling, it can also often...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...